Retrospective analysis of the financial break-even point for intrathecal morphine pump use in Korea.
10.3344/kjp.2017.30.4.272
- Author:
Eun Kyoung KIM
1
;
Ji Yeon SHIN
;
Anyela Marcela CASTAÑEDA
;
Seung Jae LEE
;
Hyun Kyu YOON
;
Yong Chul KIM
;
Jee Youn MOON
Author Information
1. Department of Anesthesiology and Pain Medicine, Seoul National University Hospital College of Medicine, Seoul, Korea. jymoon0901@gmail.com
- Publication Type:Original Article
- Keywords:
Chronic pain;
Cost;
Drug dosage calculation;
Health insurance;
Intrathecal morphine pump;
Morphine;
Patient satisfaction
- MeSH:
Chronic Pain;
Drug Dosage Calculations;
Humans;
Insurance;
Insurance, Health;
Korea*;
Morphine*;
National Health Programs;
Patient Satisfaction;
Retrospective Studies*;
Tertiary Care Centers
- From:The Korean Journal of Pain
2017;30(4):272-280
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The high cost of intrathecal morphine pump (ITMP) implantation may be the main obstacle to its use. Since July 2014, the Korean national health insurance (NHI) program began paying 50% of the ITMP implantation cost in select refractory chronic pain patients. The aims of this study were to investigate the financial break-even point and patients' satisfaction in patients with ITMP treatment after the initiation of the NHI reimbursement. METHODS: We collected data retrospectively or via direct phone calls to patients who underwent ITMP implantation at a single university-based tertiary hospital between July 2014 and May 2016. Pain severity, changes in the morphine equivalent daily dosage (MEDD), any adverse events, and patients' satisfaction were determined. We calculated the financial break-even point of ITMP implantation via investigating the patient's actual medical costs and insurance information. RESULTS: During the studied period, 23 patients received ITMP implantation, and 20 patients were included in our study. Scores on an 11-point numeric rating scale (NRS) for pain were significantly reduced compared to the baseline value (P < 0.001). The MEDD before ITMP implantation was 0.59 [IQR: 0.55–0.82]. The total MEDD increased steadily to 0.77 [IQR: 0.53–1.08] at 1 year, which was 126% of the baseline (P < 0.001). More than a half (60%) responded that the ITMP therapy was somewhat satisfying. The financial break-even point was 28 months for ITMP treatment after the NHI reimbursement policy. CONCLUSIONS: ITMP provided effective chronic pain management with improved satisfaction and reasonable financial break-even point of 28 months with 50% financial coverage by NHI program.
